Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ensem Therapeutics
AstraZeneca
Genmab
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
STORM Therapeutics LTD
Tubulis GmbH
Alentis Therapeutics AG
Eli Lilly and Company
Neonc Technologies, Inc.
Ipsen
Sumitomo Pharma America, Inc.
Terremoto Biosciences Inc.
Bristol-Myers Squibb
University of Washington
NYU Langone Health
Merus B.V.
Aulos Bioscience, Inc.
Memorial Sloan Kettering Cancer Center
Exscientia AI Limited
Amgen
University of California, Davis
One-carbon Therapeutics AB
Xinqiao Hospital of Chongqing
Radiopharm Theranostics, Ltd
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Washington University School of Medicine
Kura Oncology, Inc.
University of Colorado, Denver